Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy

[31] Teppler H(2008)Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen Enferm Infecc Microbiol Clin 26 23-12

[32] Neamati N(2009)Pharmacokinetics and interactions of raltegravir Retrovirology 6 106-32

[33] Kulkosky J(0518)Dynamics of viral replication in blood and lymphoid tissues during SIVmac251 infection of macaques J Acquir Immune Defic Syndr 43 509-29

[34] Bray S(2007)Antiretroviral activity, pharmacokinetics, and tolerability of MK- a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals Retrovirology 4 21-4818

[35] Chun TW(2008)In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate Curr HIV Res 6 306-31196

[36] Justement JS(2004)Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1 Antivir Ther 9 3-255

[37] Moir S(2009)Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV J Antimicrob Chemother 64 25-804

[38] Hallahan CW(2009)Evolution of raltegravir resistance during therapy AIDS Rev 11 17-418

[39] Maenza J(2009)Characterization and structural analysis of HIV-1 integrase conservation Bioorg Med Chem 17 4806-20367

[40] Mullins JI(2007)Analysis of binding parameters of HIV-1 integrase inhibitors: correlates of drug inhibition and resistance J Biol Chem 282 31186-901

[31] Teppler H(2008)Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen Enferm Infecc Microbiol Clin 26 23-12

[32] Neamati N(2009)Pharmacokinetics and interactions of raltegravir Retrovirology 6 106-32

[33] Kulkosky J(0518)Dynamics of viral replication in blood and lymphoid tissues during SIVmac251 infection of macaques J Acquir Immune Defic Syndr 43 509-29

[34] Bray S(2007)Antiretroviral activity, pharmacokinetics, and tolerability of MK- a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals Retrovirology 4 21-4818

[35] Chun TW(2008)In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate Curr HIV Res 6 306-31196

[36] Justement JS(2004)Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1 Antivir Ther 9 3-255

[37] Moir S(2009)Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV J Antimicrob Chemother 64 25-804

[38] Hallahan CW(2009)Evolution of raltegravir resistance during therapy AIDS Rev 11 17-418

[39] Maenza J(2009)Characterization and structural analysis of HIV-1 integrase conservation Bioorg Med Chem 17 4806-20367

[40] Mullins JI(2007)Analysis of binding parameters of HIV-1 integrase inhibitors: correlates of drug inhibition and resistance J Biol Chem 282 31186-901